IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roger Cranwill who wrote (141)	12/1/1996 11:24:00 PM
From: I. Luttichuys	of 1762

Hello Roger, I've seen what you mean about r*lly. I have owned IDEC through a couple of down-turns and have seen this before. It drops down about 30-50%, I buy all the way down, it turns around. I don't think I am being overly confident in saying that most who are following this stock are anticipating the content of Phase III presented DEC 6 on C2B8. When Phase II was released on same, stock went up sharply. I think that what we are seeing now is postioning by those who are expecting good news and reluctance to sell by those already where they want to be. The result is we seem to be up every day as we move to DEC 6. I do not think this is going to change dramatically barring anything unexpected. The sell-off that occured recently has been nothing more than an opportunity for those of us who understand the value of C2B8 and other therapies in IDEC's pipeline. Although I have heard some say "well IDEC isn't making any money so its over-valued and that's why the sell-off", I don't really buy it. It is notoriously expensive to bring a new drug to market and it is quite common to see biotechs losing $1-2/share with stock at $40-60/share. Here's IDEC losing .24/share and trading for 24/share. I have followed IDEC for some time and have nothing but alot of good things to say about the company. Will it continue as it is now? I don't know but, over the long haul, IDEC appears to be pulling something off in the area of CA therapy here which is new and exciting. They are ahead of the competition in an area which is truly state-of-the-art. The market knows that IDEC and GNE are scaling up production and that IDEC seems to be preparing to market C2B8 in other ways as well. I believe we will see this stock continue to move, all other things being equal, over the long haul. Therefore, I did not sell it during the down-turn. I only bought. This strategy has done me well so far and I see no reason to change it. In short, I believe you are correct to be optimistic. BENNETT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next